Cytoreductive surgery (CRS) is a surgical procedure that aims to reduce the amount of cancer cells in the abdominal cavity for patients with tumors that have spread intraabdominally (peritoneal carcinomatosis).
Its main developer was Paul Sugarbaker, who is known for the development of cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy,[1] or HIPEC, a treatment alternately referred to as the Sugarbaker Procedure.
[2][3] Among patients with stage III epithelial ovarian cancer, the addition of HIPEC to interval cytoreductive surgery resulted in longer recurrence-free survival and overall survival than surgery alone and did not result in higher rates of side effects.
[5] In a typical case an incision is made from the sternum down to the pelvis, and cancerous cells are removed.
Then heated chemotherapy liquid is poured in to destroy remaining cells.